medRxiv preprint doi: https://doi.org/10.1101/2020.08.06.20169276; this version posted August 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

The implementation of a rapid sample preparation method

2 for the detection of SARS-CoV-2 in a diagnostic laboratory

3 in South Africa

4 Gert Marais^{1,3*}, Michelle Naidoo^{1,3}, Nei-yuan Hsiao^{1,3}, Ziyaad Valley-Omar^{1,2}, Heidi Smuts^{1,3}, 5 6 Diana Hardie^{1,3} 7 8 ¹Division of Medical Virology, University of Cape Town, Cape Town, Western Cape, South 9 Africa 10 11 ²Groote Schuur Hospital Tissue Immunology Diagnostic Laboratory, National Health 12 Laboratory Service, Cape Town, Western Cape, South Africa 13 14 ³Groote Schuur Hospital Virology Diagnostic Laboratory, National Health Laboratory Service, 15 Cape Town, Western Cape, South Africa 16 17 *Corresponding author E-mail: gert.marais16@alumni.imperial.ac.uk (GM) 18 19

21 Abstract

22

The SARS-CoV-2 pandemic has resulted in shortages of both critical reagents for nucleic acid 23 24 purification and highly trained staff as supply chains are strained by high demand, public health 25 measures and frequent quarantining and isolation of staff. This created the need for alternate 26 workflows with limited reliance on specialised reagents, equipment and staff. We present here 27 the validation and implementation of such a workflow for preparing samples for downstream 28 SARS-CoV-2 RT-PCR using liquid handling robots. The rapid sample preparation technique 29 evaluated, which included sample centrifugation and heating prior to RT-PCR, showed a 30 97.37% (95% CI: 92.55-99.28%) positive percent agreement and 97.30% (95% CI: 90.67-31 99.52%) negative percent agreement compared to nucleic acid purification-based testing. This 32 method was subsequently adopted as the primary sample preparation method in the Groote 33 Schuur Hospital Virology Diagnostic Laboratory in Cape Town, South Africa.

34

35 Introduction

36

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), an emergent
betacoronavirus, was identified as a novel causative agent of severe pneumonia in Wuhan,
China in 2019 [1]. The capacity for person-to-person transmission was soon identified and the
ensuing pandemic has caused more than seventeen million cases at the time of submission [2].

42 Currently, diagnostic testing for SARS-CoV-2 relies on molecular techniques, primarily
43 reverse-transcriptase polymerase chain reaction (RT-PCR), from respiratory specimens [3].
44 The specialised equipment and reagents required to offer these tests at scale has placed

45 significant strain on worldwide supply chains of reagents. Public health measures put in place 46 in numerous countries, including travel restrictions, have further made planning for sustainable 47 service delivery difficult as laboratory stock orders may not be filled on time. These issues 48 motivate for the use of diagnostic workflows that favour locally or readily available reagents to, at least partially, insulate supply chains from fluctuations in global demand and evolving 49 50 travel limiting public health measures. To address these issues, a number of laboratories have 51 successfully developed alternative sample preparation techniques which limit reagent needs 52 and avoid complex nucleic acid (NA) purification protocols [4-6]. There is also a significant 53 cost saving when the reagent-free direct heating method, as described by Fomsgaard and 54 Rosenstierne [4], is used which will become critical if economic fallout from the pandemic intensifies. Staff shortages in the laboratory are an inevitability as social distancing 55 56 requirements are implemented in concert with increasing demand for diagnostic testing. SARS-57 CoV-2 outbreaks in the laboratory environment may also introduce unpredictable shortages of 58 critical staff further limiting the capacity of laboratories to offer predictable test turnaround 59 times. The necessary influx of new staff, who may have limited training or training in a related field, can further compromise the reliability of diagnostic laboratory services as the capacity 60 61 for oversight and quality control is hindered by rapidly evolving testing demands and workflow 62 instability due to reagent shortages and potentially unreliable testing kits due to limited 63 regulatory oversight [7]. All these factors highlight the need for automated workflows that limit 64 the number of laboratory staff-dependent steps and in particular steps requiring specialised 65 training. Automation further limits human error such as sample switches and cross-66 contamination and are generally amenable to greater degrees of workflow control due to 67 traceable instrument log files.

A chemical reagent-free heat-based rapid sample preparation (RSP) method for downstream
SARS-CoV-2 RT-PCR amplification is presented here optimised for use on automated liquid
handling robots.

72

73 Materials and methods

74

75 Ethics

76

Biological material of human origin was anonymised and all clinical and other personally
identifiable data delinked with only study specific sample identifiers used along with sample
SARS-CoV-2 assay performance data. Ethics approval for this work was granted by the
University of Cape Town Human Research Ethics Committee (HREC reference number:
335/2020).

82

83 Sample selection

84

Nasopharyngeal (NP) and oropharyngeal (OP) swabs sent dry or in saline to the National Health Laboratory Service Virology Diagnostic Laboratory in Groote Schuur Hospital from its standard referral area for SARS-CoV-2 testing were included. 115 samples which tested positive and 80 samples which tested negative for SARS-CoV-2 by NA purification-based commercial diagnostic assays in use at the diagnostic laboratory were selected. Spectrum bias was avoided by selecting consecutive samples that tested positive by standard testing over two discrete intervals of regular laboratory workflow. Samples that tested negative were selected

92 randomly from the same intervals. The diagnostic assays in use were the Abbott RealTime 93 SARS-CoV-2 Assay (Abbott Laboratories, USA) running on the Abbott m2000 RealTime 94 system and the AllplexTM 2019-nCoV assay (Seegene, South Korea). The assays were run as 95 per package insert. The AllplexTM 2019-nCoV assay was performed after sample NA 96 purification using the NucliSENS[®] easyMag[®] (bioMérieux, France) as per package insert.

97

98 Rapid sample preparation

99

Standard diagnostic testing sample preparation included placing NP or OP swabs in a 2ml Sarstedt sample tube containing 1.5ml autoclaved 0.9% saline. If both a NP and OP swab or multiple swabs of the same type was received, they were combined in a single tube. The swabs were cut to fit in the tube. The tube was then vortexed for 10 seconds. The saline was used as the sample input for downstream assays after which the tube was stored at 4°C. Stored tubes from diagnostic samples were available for inclusion in the study.

106

Selected sample tubes were centrifuged at 16 000 g for 5 minutes and 50µl of the supernatant was then pipetted into the wells of a 96-well PCR plate. The PCR wells were capped and the plate incubated on a thermocycler at 98°C for 5 minutes followed by 4°C for 2 minutes. The PCR plate was then briefly centrifuged and placed on a dedicated QIAgility (Qiagen, Germany) liquid handling instrument for sample-addition.

112

RT-PCR after rapid sample preparation 114

115

116 Concurrent with sample preparation, a second dedicated QIAgility instrument was used for Allplex[™] 2019-nCoV assay master mix preparation and aliquoting into appropriate 8-well 117 118 PCR strips (Bio-Rad Laboratories, USA). Following master mix preparation, the PCR strips 119 were transferred to the sample-addition QIAgility instrument. The sample input volume and 120 master mix constituents are shown in Table 1.

121

	Volume per
	reaction (µl)
RNase-free Water	11.1
2019-nCoV MOM (primer and probe mix)	6
5X Real-time One-step Buffer	6
Real-time One-step Enzyme	2.4
Internal control (RP-IC)	1.5
Sample after centrifugation and heating	3
Total volume	30

Table 1. RT-PCR reaction preparation 122

124 After sample addition, the PCR strips were sealed and briefly centrifuged before being loaded 125 on a CFX96TM Real-Time PCR Detection System (Bio-Rad Laboratories, USA). The real-time PCR cycling parameters recommended by the AllplexTM 2019-nCoV assay package insert were 126 127 used unchanged. Real-time data analysis was performed using the 2019-nCoV Viewer for Real time Instruments V3 (Ver 3.18.005.003) software as per the Allplex[™] 2019-nCoV assay 128 129 package insert.

130

131 If the internal control (RP-IC) was not detected with a cycle threshold (Ct) value <40, the 132 primary sample was retested with a decreased sample volume input. The sample input for 133 repeat testing and master mix constituents are shown in Table 2. The remainder of the protocol 134 was unchanged.

135

136	Table 2. RT-PCR	reaction prepara	tion for repeat testing
-----	-----------------	------------------	-------------------------

	Volume per
	reaction (µl)
RNase-free Water	12.1
2019-nCoV MOM (primer and probe mix)	6
5X Real-time One-step Buffer	6
Real-time One-step Enzyme	2.4
Internal control (RP-IC)	1.5
Sample after centrifugation and heating	2
Total volume	30

137

138 Repeatability and analytical sensitivity

Inter-assay reproducibility was assessed using 8 samples with Envelope (E) gene Ct values ranging between 17.16 and 35.63, which were tested in triplicate 7 days after initial testing. Intra-assay reproducibility was assessed by repeating 16 samples in triplicate. Samples were stored at 4°C while awaiting repeat testing. To assess the relative analytical sensitivity of the RSP method, a sample was selected and serially diluted with saline and tested with multiple replicates at each dilution after both NA purification and RSP using the Allplex[™] 2019-nCoV

146 assay. The dilution at which SARS-CoV-2 RNA could be detected with 95% confidence was
147 determined for each method by Probit analysis. The absolute analytical sensitivity of the RSP
148 method was calculated based on the relative analytical sensitivity compared to NA purification149 based detection.

150

151 Statistical analysis and graphics

152

Data visualisation and statistical analysis, including paired t-tests for comparison of target Ct values, a Fisher's exact test for statistical significance determination of the positive percent agreement (PPA) and negative percent agreement (NPA) with NA extraction-based testing and the Wilson/Brown method for 95% confidence interval determination, was done using GraphPad Prism version 8.4.2 for macOS, GraphPad Software, San Diego, California USA, www.graphpad.com.

159 **Results and discussion**

160

161 115 samples which tested positive and 80 samples which tested negative for SARS-CoV-2 by 162 NA purification-based testing were tested using the RSP method. The Allplex[™] 2019-nCoV 163 assay result after RSP correlated for 111 and 72 samples respectively as shown in Table 3. One 164 sample that tested positive and 6 samples that tested negative were excluded. Raw data is 165 shown in the S1 Appendix.

167 Table 3. Contingency table used for positive and negative percent agreement with NA

168 purification-based testing calculation

	Positive SARS-CoV-2 Abbott RealTime SARS-CoV-2 Assay or Seegene Allplex TM 2019-nCoV Assay	Negative SARS-CoV-2 Abbott RealTime SARS-CoV-2 Assay or Seegene Allplex TM 2019-nCoV Assay
	NA Purification	NA Purification
Positive SARS-CoV-2, RSP	111	2
method, Seegene Allplex TM 2019-		
nCoV Assay		
Negative SARS-CoV-2, RSP	3	72
method, Seegene Allplex TM 2019-		
nCoV Assay		

169

170 The PPA and NPA of the RSP method with NA purification-based testing for SARS-CoV-2 171 demonstrated a P value of <0.0001. The PPA of the RSP method was 97.37% (95% CI: 92.55-172 99.28%) and the NPA 97.30% (95% CI: 90.67-99.52%). The 6 negative samples that were 173 excluded from RSP testing and analysis were excluded because the internal control failed to 174 amplify primarily and after repeat testing with a reduced sample input volume. This was likely 175 due to sample-specific PCR inhibitors. The positive sample that was excluded could not be 176 tested by RSP due to breakdown of the nasopharyngeal swab leading to excessive viscosity. 177

178 The Ct values of individual targets of the Allplex[™] 2019-nCoV assay were assessed for 179 samples prepared by NucliSENS® easyMag® NA purification and RSP. The E gene, RNA-

dependent RNA-polymerase (RdRp) gene and Nucleocapsid (N) gene targets had Ct values
that were significantly different with a P value of <0.0001 (Fig 1). The mean difference in Ct
values between RSP and NA purification was 2.148 (95% CI: 1.909-2.387) for the E gene,
3.271 (95% CI: 3.037-3.506) for the RdRp gene and 1.608 (95% CI: 1.407-1.809) for the N
gene, with RSP demonstrating a greater mean Ct value in each case.



185

Fig 1. Comparison of target Ct values after RSP and NucliSENS® easyMag NA purification. The Ct values for the SARS-CoV-2 (A) Envelope (E), (B) RNA-dependent RNApolymerase (RdRp) and (C) Nucleocapsid (N) gene targets are shown for samples tested with the AllplexTM 2019-nCoV assay after NucliSENS® easyMag® NA purification and RSP. The difference in generated Ct values was found to be statistically significant in each case with a P value of <0.0001 as determined by paired t-test.

193 The difference in mean Ct values between RSP and NA purification based testing allowed the 194 PPA to be further estimated as 95.96% (95% CI: 92.23-97.94%). This was done by 195 retrospectively reviewing the results of samples with target amplification between 1 April 2020

and 24 April 2020 that were prepared for testing by NucliSENS® easyMag® NA purification.
The mean Ct difference values for each gene target (E, RdRp, N) were added to their respective
target Ct value. If this generated a value above 40, that gene target was deemed unlikely to be
detected after RSP. If all three gene targets were deemed unlikely to be detected, the sample
was classified as an expected negative. 198 previously positive samples were assessed in this
manner and 8 were classified as RSP-expected negatives thus allowing the calculation of the
above estimated PPA.

203

- 204 The relative performance of the Abbott RealTime SARS-CoV-2 assay and the AllplexTM 2019-
- 205 nCoV assay after RSP is shown in Fig 2. The Abbott assay reports cycle number (CN) values
- which are not equivalent to Ct values and thus are not directly comparable.

208



209

210 Fig 2. Comparison of target Ct and CN values after RSP and testing with the Abbott 211 RealTime SARS-CoV-2 assay. The Ct values for the SARS-CoV-2 Envelope, RNA-212 dependent RNA-polymerase and Nucleocapsid gene targets are shown for samples tested with 213 the Allplex[™] 2019-nCoV assay after RSP and CN values after testing with the Abbott 214 RealTime SARS-CoV-2 assay are shown. A plotted CN or Ct value of 40 indicates that 215 detectable amplification did not occur. The Abbott assay CN values are assay specific and not 216 directly comparable to Ct values, but are shown to demonstrate the performance of the 217 spectrum of selected samples.

The single false negative result from the RSP method when compared to NucliSENS® easyMag® NA purification was from a sample that only tested positive for one of the three Allplex[™] 2019-nCoV targets, the N gene, with a Ct value of 36.7. The two false negatives from the RSP method when compared to the Abbott RealTime SARS-CoV-2 Assay, which includes NA purification, had high CN values. However, samples with higher CN values were detected thus sample-specific inhibition may also have played a role.

225

There were two false positive results from the RSP method when compared to the Abbott RealTime SARS-CoV-2 Assay. A single target was detected in both cases with Ct values above 35. This may represent contamination events or the samples may have viral RNA at levels near the limit of detection for both assays. NA contamination in the laboratory is monitored for by frequent testing of environmental swabs and reagent blanks. Multiple negative controls are also included in each run.

232

The intra-assay repeatability assessment of mean Ct values for the three Allplex[™] 2019-nCoV
targets showed a coefficient of variance of 1.14%. The inter-assay repeatability assessment of
mean Ct values after 7 days of sample storage showed a coefficient of variance of 1.27%.

236

The relative analytical sensitivity of the Allplex[™] 2019-nCoV assay after RSP was found to be 807 RNA copies per reaction. This was calculated from the 8.07-fold decrease in analytical sensitivity of the RSP method compared to NucliSENS® easyMag® NA purification-based testing, which has an analytical sensitivity of 100 RNA copies per reaction as per the Allplex[™] 2019-nCoV assay package insert. The relative decrease was determined by serially diluting and testing a sample with multiple replicates as shown in Table 4. This relative loss in analytical sensitivity can largely be explained by the decrease sample input volume for RSP.

NucliSENS® easyMag® NA purification concentrates sample nucleic acids by a factor of approximately 2, based on sample input versus elution volume. Additionally, the AllplexTM 2019-nCoV assay input volume after NA purification is 8μ l versus the 3μ l sample input volume for RSP. Thus, the expected loss in analytical sensitivity would be 5.3-fold which is comparable to the experimentally determined loss of 8.07-fold and suggests that sample inhibition plays a minor role. Raw data is shown in the S2 Appendix.

250

Dilution	Replicates	Seegene Allplex TM 2019-nCoV	Seegene Allplex TM 2019-nCoV
		Assay	Assay
		RSP Method	NA Purification
		Percentage of Samples Positive	Percentage of Samples Positiv
1:20	24	100%	Not done
1:40	24	95.8%	Not done
1:80	24	70.8%	Not done
1:120	24	58.3%	Not done
1:160	24	41.7%	Not done
1:200	10	Not done	100%
1:320	24	33.3%	Not done
1:400	10	Not done	100%
1:500	10	Not done	90%
1:625	10	Not done	70%
1:2000	10	Not done	60%
1:5000	10	Not done	30%

251 Table 4. Relative analytical sensitivity assessment

The performance characteristics were deemed acceptable for clinical diagnostic use in the Groote Schuur Hospital Virology Diagnostic Laboratory and allowed the laboratory to increase the number of samples tested daily by a factor of 5-10 due to the decreased supply chain dependence and simplified workflow. The reduced processing time further facilitated a more rapid test turnaround time which was beneficial for in-hospital infection control. A stable workflow, not subject to reagent availability dependent variations, also decreased laboratory errors and may allow for improved clinical planning as a result of a stable test turnaround time.

260

261 The implementation of the RSP method in our laboratory initially involved implementation of 262 an earlier version of the protocol, Protocol 1 in the S1 Appendix, where steps were performed 263 manually and an altered master mix formulation was used. This version of the protocol showed 264 significant operator dependency with numerous invalid results occurring when new operators performed the assay. The performance issues were most often related to the mixing of the 265 266 master mix, which must be thorough, and to delays between assay steps. In particular, master 267 mix with added sample was only stable for a brief period before decay and must thus be rapidly placed on the thermocycler. This operator dependency and fluctuating staff availability 268 269 motivated for the further automation of the process with liquid handling robots.

270

The laboratory approach to result interpretation was also affected by the implementation of the RSP method. The approach to NucliSENS® easyMag® NA purification-prepared samples involved release of numerous inconclusive results, despite multiple target amplification at times, due to the known capacity for sample contamination both on the easyMag® instrument and during processing of swabs. The known decrease in sensitivity of the RSP method and the lack of use of the easyMAG® open system for processing, decreased the number of inconclusive results released by our laboratory.

278

NA purification is the gold-standard in sample processing for RT-PCR, however, in the setting of a pandemic with significant pressures on reagent supply chains and the need for a rapid increase in testing capacity, the RSP method described here presented a reasonable alternative and has been implemented as the primary sample preparation method in the Groote Schuur Hospital Virology Diagnostic Laboratory in South Africa.

284

285 **References**

287	1.	Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu
288		P. A novel coronavirus from patients with pneumonia in China, 2019. New England
289		Journal of Medicine. 2020 Jan 24.
290	2.	World Health Organisation. Coronavirus Disease (COVID-19) Situation Report
291		[Internet]. Geneva: WHO; Data as received by WHO from national authorities by
292		10:00 CEST, 2 August 2020 [cited 2020 August 3]. 16 p. Situation Report - 195.
293		Available from: https://www.who.int/docs/default-source/coronaviruse/situation-
294		reports/20200802-covid-19-sitrep-195.pdf?sfvrsn=5e5da0c5_2.
295	3.	Tang YW, Schmitz JE, Persing DH, Stratton CW. The laboratory diagnosis of COVID-
296		19 infection: current issues and challenges. Journal of clinical microbiology. 2020 Apr
297		3.
298	4.	Fomsgaard AS, Rosenstierne MW. An alternative workflow for molecular detection of
299		SARS-CoV-2-escape from the NA extraction kit-shortage, Copenhagen, Denmark,
300		March 2020. Eurosurveillance. 2020 Apr 9;25(14):2000398.

301	5.	Ladha A, Joung J, Abudayyeh O, Gootenberg J, Zhang F. A 5-min RNA preparation
302		method for COVID-19 detection with RT-qPCR. medRxiv. 2020 Jan 1.

- 303 6. Smyrlaki I, Ekman M, Vondracek M, Papanicoloau N, Lentini A, Aarum J, Muradrasoli
- 304 S, Albert J, Högberg B, Reinius B. Massive and rapid COVID-19 testing is feasible by
- 305 extraction-free SARS-CoV-2 RT-qPCR. medRxiv. 2020 Jan 1.
- 306
 7. Abbasi J. The promise and peril of antibody testing for COVID-19. JAMA. 2020 May
 307
 19;323(19):1881-3.